Clinical trial phases, explained: what phase 1, 2, 3 and 4 tell you
Phase labels appear in every drug-pipeline headline. Here is what each phase is designed to answer, how large the studies typically are, and what a phase label does not tell you.
The signal
FDA describes four phases of clinical research: phase 1 focuses on safety and dosage, phase 2 on efficacy and side effects, phase 3 on efficacy and monitoring of adverse reactions in larger groups, and phase 4 on safety and efficacy after approval.
Why this matters
Pipeline news is easier to weigh when you know what stage a study is at: an early-phase result answers different questions from a large phase 3 trial, and every therapy still in trials is investigational.
The 2-minute brief
Drug development in people moves through phases. Phase 1 studies a small group for safety and dosage; phase 2 looks at efficacy and side effects in up to several hundred people; phase 3 tests efficacy and monitors adverse reactions in roughly 300 to 3,000 people; phase 4 continues to study safety and efficacy after approval.
A phase tells you what a study was designed to answer and roughly how large it is. It does not tell you whether the drug works, and every therapy still in trials is investigational for the use being studied.
What changed
- Phase 1 studies typically involve 20 to 100 healthy volunteers or people with the disease or condition and focus on safety and dosage.[1]
- Phase 2 studies involve up to several hundred people with the disease or condition and focus on efficacy and side effects.[1]
- Phase 3 studies involve roughly 300 to 3,000 volunteers who have the disease or condition and focus on efficacy and monitoring of adverse reactions.[1]
- Phase 4 studies take place after approval, involve several thousand volunteers who have the disease or condition, and focus on safety and efficacy.[1]
- ClinicalTrials.gov records each registered study’s phase together with its recruitment status and sponsor.[2]
Who this affects
- Pharmacists
- Prescribers
- Weight-management clinics
- Medical directors
- Healthcare executives
What to watch next
Status changes and newly posted results for the studies on the GLP-1 & Obesity Drug Pipeline tracker.[2]
NPHLA takeaway
Read a phase label as a description of the study, not a verdict on the drug. Results from any phase need the full published data, and approval decisions come only from FDA. General information, not medical advice.
Source file
- [1]
- [2]
Drafted with AI assistance from the sources listed in the Source File, then reviewed and approved by an NPHLA editor before publication. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.